Abstract No. 236 Comparison of 30-day readmission rate and mortality risk using a controlled expansion endoprosthesis or a conventional covered endoprosthesis: a single-center, retrospective study

Abstract

To compare 30-day readmission rates and 1-year mortality risk after transjugular intrahepatic portosystemic shunt (TIPS) creation using either a controlled expansion endoprosthesis (Viatorr; VCX) or a standard endoprosthesis (Viatorr; VTS). A total of 160 patients who underwent TIPS creation with VTS and 123 who underwent TIPS creation with VCX between January 1, 2015, and December 31, 2019, were included in this retrospective study. Patients with incomplete medical history or follow-up data were excluded. Cox proportional regression and multivariable logistic regression analyses were used to compare survival and readmission rates, respectively. Baseline characteristics, portosystemic gradient change, and 30-day shunt patency rates were similar between the groups. The 30-day readmission rate was lower in the VCX group than in the VTS group (7.3% vs 30.0%; P < 0.001). The most common indication for readmission was hepatic encephalopathy–related confusion (9.4% for VTS; 4.9% for VCX). Regression analysis demonstrated that the use of VCX was associated with a lower 30-day readmission rate (hazard ratio = 0.81; P < 0.001), whereas the development of hepatic encephalopathy was associated with a higher readmission rate (hazard ratio = 1.21; P = 0.001). The 30-day, 90-day, and 1-year mortality rates were 8.2%, 14%, and 21%, respectively, with VTS group and 11%, 13%, and 26%, respectively, with VCX (P = 0.43). The use of VCX was associated with a significantly lower 30-day readmission rate when compared with the use of VTS, but 1-year mortality rates were similar for the groups.